Manufacturing Compliance Updates In Brief From US FDA And EU
Executive Summary
After import alerts to five facilities in China, Austria, and Australia, US FDA follows up with warning letters; meanwhile, another firm in China receives notice of non-compliance with EU GMP requirements.Shanwei Honghui, Wuham Moxibustion, Yicheng Chemical, Schrofner Cosmetics, Delta Labs, and Inner Mongolia Changsheng among firms now in regulatory cross hairs.
You may also be interested in...
US FDA Crossing Off More Foreign OTC Firms On Globalization Checklist
FDA issued 39 warning letters to OTC drug facilities, most of them outside the US, in 2017, a number significantly boosted by an initiative to inspect a total of 1,000 foreign drug manufacturers from January 2017 through September 2019 , says CDER compliance director Donald Ashley. Many GMP violations behind FDA's warning letters concerned “rudimentary" requirements.
US FDA Crossing Off More Foreign OTC Firms On Globalization Checklist
FDA issued 39 warning letters to OTC drug facilities, most of them outside the US, in 2017, a number significantly boosted by an initiative to inspect a total of 1,000 foreign drug manufacturers from January 2017 through September 2019 , says CDER compliance director Donald Ashley. Many GMP violations behind FDA's warning letters concerned “rudimentary" requirements.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”